ClinicalTrials.gg
Not yet recruitingNCT07062133Updated Sep 4, 2025

Effectiveness of Electrical Pudendal Nerve Stimulation for Neurogenic Lower Urinary Tract Dysfunction in Pediatric Tethered Cord Syndrome Post-Surgery

An interventional study of Electrical pudendal nerve stimulation and Conventional conservative treatment in Postoperative Neurogenic Lower Urinary Tract Dysfunction Secondary to Tethered Cord Syndrome, sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian. Not yet recruiting at 1 site in China. Open to participants aged 3 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
3 Years to 18 Years
Sex
All
01

Study summary

The goal of this prospective observational study is to evaluate whether the addition of electrical pudendal nerve stimulation (EPNS) to standard conservative treatment can improve bladder function in pediatric patients with postoperative neurogenic bladder secondary to tethered cord syndrome . The study population consists of 50 children diagnosed with neurogenic bladder of various etiologies.

The main questions this study aims to answer are:

Does EPNS lead to significant improvement in neurogenic bladder symptom scores?

How does EPNS affect secondary clinical outcomes such as renal function, post-void residual volume, urinary leakage, and vesicoureteral reflux?

Researchers will compare clinical indicators before and after the addition of EPNS, on the background of consistent conservative management, to assess its therapeutic contribution.

Participants will:

Receive routine conservative therapy for neurogenic bladder (e.g., medications, bladder training)

Undergo EPNS sessions over a specified treatment period

Be evaluated using standardized scales and imaging or laboratory tests to monitor changes in bladder and renal function

The study will also explore whether treatment effects differ by underlying cause or symptom pattern.

Read the detailed description

This prospective, controlled clinical study aims to evaluate the therapeutic efficacy of "sacral four-needle" electrical pudendal nerve stimulation (EPNS) in children with neurogenic lower urinary tract dysfunction (NLUTD) following surgical untethering for tethered cord syndrome (TCS). TCS is a common spinal dysraphism in pediatrics, often resulting in bladder dysfunction postoperatively despite timely surgical intervention. Conventional management, including intermittent catheterization and pharmacotherapy, carries limitations such as poor adherence and persistent symptoms. EPNS, a non-invasive acupuncture-based neuromodulation technique targeting the pudendal nerve via anatomically guided deep needling and low-frequency electrical stimulation, has shown promise in adult neurogenic bladder cases. This study will enroll approximately 50 children aged 3-18 with confirmed TCS and persistent NLUTD after initial surgery. Participants will be assigned to receive either routine conservative therapy alone or combined with EPNS over a four-week period (three sessions per week). Treatment efficacy will be assessed through changes in the Neurogenic Bladder Symptom Score (NBSS), along with secondary endpoints including post-void residual volume, voiding frequency, episodes of incontinence, renal function, and incidence of urinary tract infections. Follow-up will continue for six months post-treatment to evaluate sustained effects. The study employs blinded outcome assessment, with standardized protocols for needling, stimulation parameters, and symptom tracking. It further includes subgroup analyses based on disease etiology and symptom type (storage vs. voiding dysfunction). The research integrates traditional acupuncture with neuroanatomical precision and modern bladder rehabilitation theory, aiming to establish a replicable, low-cost, and scalable pediatric bladder dysfunction intervention model. By addressing a current gap in pediatric urological rehabilitation, the study seeks to contribute evidence toward standardizing EPNS as a viable adjunct therapy in this vulnerable population.

02

Conditions studied

  • Postoperative Neurogenic Lower Urinary Tract Dysfunction Secondary to Tethered Cord Syndrome

Browse trials for

Keywords

  • Neurogenic Lower Urinary Tract Dysfunction
  • Tethered Cord Syndrome
  • Electrical Pudendal Nerve Stimulation
03

In context

Neural Tube Defects

47 studies on the registry are indexed under Neural Tube Defects; 9 are open to participants now.

This study's planned enrollment of 50 is close to the median of 47 across 26 interventional studies indexed under Neural Tube Defects.

Browse Neural Tube Defects studies →

Lead sponsor

Shanghai Institute of Acupuncture, Moxibustion and Meridian is the lead sponsor of 29 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 3-18 years
  • Diagnosed with TCS (by spinal MRI) and NLUTD (by urodynamic study)
  • First-time detethering surgery completed
  • Be able to comply with acupuncture treatment and follow-up
  • obtained from legal guardian

Exclusion criteria

Exclusion Criteria:

  • Severe systemic diseases
  • Current urinary tract infection, severe VUR, hydronephrosis, structural obstruction
  • Prior aggressive urological surgery (e.g., augmentation cystoplasty)
  • Prior or planned pudendal/sacral nerve implant
  • Botulinum toxin injection within past 12 months
  • Planned reoperation within 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    control group

    Conventional conservative treatment including medications (e.g., oxybutynin), clean intermittent catheterization, and diaper use as needed, without EPNS intervention.

    Other: Conventional conservative treatment

  • Experimental
    EPNS group

    Electrical Pudendal Nerve Stimulation (EPNS) delivered by four deep acupuncture needles targeting bilateral sacrococcygeal points near the pudendal nerve. Connected to G6805-2 electrical stimulator, 2 Hz, 60 minutes/session, three times per week for 4 weeks. Apart from EPNS, intervention administered in this group also include conventional conservative treatment as sama as in the control group

    Procedure: Electrical pudendal nerve stimulation · Other: Conventional conservative treatment

Interventions

  • ProcedureElectrical pudendal nerve stimulation

    Electrical Pudendal Nerve Stimulation (EPNS) delivered by four deep acupuncture needles targeting bilateral sacrococcygeal points near the pudendal nerve. Connected to G6805-2 electrical stimulator, 2 Hz, 60 minutes/session, three times per week for 4 weeks.

  • OtherConventional conservative treatment

    Conventional conservative treatment including medications (e.g., oxybutynin), clean intermittent catheterization, and diaper use as needed

06

What researchers measure

Primary outcomes

  1. Change in Neurogenic Bladder Symptom Score (NBSS) from baseline to 4 weeks post-treatment

    The Neurogenic Bladder Symptom Score (NBSS) is a validated, patient-reported questionnaire specifically designed to evaluate urinary symptoms and quality of life in individuals with neurogenic lower urinary tract dysfunction (NLUTD). It includes domains assessing incontinence, storage and voiding symptoms, complications (such as infections or catheter use), and the impact on daily life. In this study, the NBSS will be administered at baseline (prior to treatment initiation) and again after the 4-week intervention period. The primary outcome measure will be the change in total NBSS score between these two time points. A decrease in NBSS score reflects symptom improvement. Assessments will be completed by participants or their guardians under guidance from trained study personnel.

    Time frame: Baseline to 4 weeks (end of treatment)

Secondary outcomes

  1. Serum creatinine and estimated glomerular filtration rate (eGFR)

    Serum creatinine and estimated glomerular filtration rate (eGFR) are standard laboratory measures used to evaluate renal function. Serum creatinine reflects the concentration of creatinine in the blood, a waste product filtered by the kidneys, while eGFR provides an estimate of kidney filtration efficiency adjusted for age, sex, and body size.

    Time frame: Baseline, 4 weeks, and 6-month follow-up

  2. Change in post-void residual urine volume (PVR)

    Post-void residual urine volume (PVR) is a clinical parameter used to assess the efficiency of bladder emptying. It is defined as the amount of urine remaining in the bladder immediately after voluntary urination. In this study, PVR will be measured using noninvasive bladder ultrasound (portable or bedside ultrasound device) performed by trained personnel.A reduction in PVR indicates improved bladder emptying function, which is a critical component of managing NLUTD.

    Time frame: Baseline, after 5th session, 10th session, end of treatment (week 4), and at 2-, 4-, 6-month follow-up

  3. Urinary leakage volume

    Time frame: Baseline to 4 weeks, and at 2-, 4-, and 6-month follow-up

  4. Incidence or grade of vesicoureteral reflux (VUR)

    Vesicoureteral reflux (VUR) is the retrograde flow of urine from the bladder into the ureters and potentially the kidneys, which can contribute to recurrent urinary tract infections and renal damage.The outcome will include (1) the presence or absence of VUR and (2) any change in VUR grade among participants with reflux at baseline. The primary interest is in identifying any improvement (reduction in grade or resolution) or worsening of VUR following the intervention.

    Time frame: Baseline and 6-month follow-up

07

Study locations

1 site
  • Shanghai Pudong Hospital of Traditional Chinese Medicine
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: Undecided — This is an early-phase, single-center exploratory trial with a limited sample size. The primary goal is to generate pilot data for future large-scale studies. At present, there is no confirmed plan to share de-identified individual participant data (IPD). However, data sharing may be considered in the future depending on study outcomes, ethical approvals, and publication status. If data are made available in the future, access will be provided to qualified researchers upon reasonable request and subject to institutional data use agreements and ethical oversight.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2025; primary completion for Jan 2027, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 14, 2025
StartEst.
Nov 1, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07062133
Lead sponsor
Shanghai Institute of Acupuncture, Moxibustion and Meridian
Collaborators
Shanghai Pudong Hospital of Traditional Chinese Medicine
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Nov 1, 2025 (estimated)
Primary completion
Jan 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Sep 4, 2025

Study contacts

Wang Siyou, Professor
Contact
wangsiyou1234@163.com
86-13916145894

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion